Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;93(8):600-608.
doi: 10.2183/pjab.93.038.

Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease

Tsutomu Takeuchi  1
Affiliations
Review

Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease

Tsutomu Takeuchi. Proc Jpn Acad Ser B Phys Biol Sci. 2017.

Erratum in

Abstract

Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to the patients and societies. Here, I will review recent progress of the biological treatment in the immune-inflammatory diseases by focusing on the rheumatoid arthritis, the disease characterized by persistent polyarthritis leading to joint destruction and disability with autoimmune features, as a role model.

Keywords: biologics; cytokines; immune-mediated inflammatory diseases; rheumatoid arthritis; therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Clinical and pathological characteristics of rheumatoid arthritis.
Figure 2.
Figure 2.
Pathogenesis of rheumatoid arthritis.
Figure 3.
Figure 3.
Structure of biologics.
Figure 4.
Figure 4.
Cytokine cascade hypothesis in rheumatoid arthritis.
Figure 5.
Figure 5.
Timing of introduction of biologics in rheumatoid arthritis. Clinical studies of tocilizumab monotherapy.
See this image and copyright information in PMC

References

    1. Kuek A., Hazleman B.L., Ostor E.L. (2007) Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 83, 251–260. - PMC - PubMed
    1. Davidson A., Diamond B. (2001) Autoimmune diseases. N. Engl. J. Med. 345, 340–350. - PubMed
    1. Kopf M., Bachmann M.F., Marsland B.J. (2010) Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9, 703–718. - PubMed
    1. McInnes I.B., Schett G. (2011) The pathogensis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219. - PubMed
    1. Smolen J.S., Aletaha D., McInnes I.B. (2016) Rheumatoid arthritis. Lancet 388, 2023–2038. - PubMed

MeSH terms